Trajan Group (TRJ) H1 2025 earnings summary

Executive summary

• Achieved record H1 FY25 net revenue of $81.0M, up 6.0% year-over-year, with strong growth in Capital Equipment and Components & Consumables segments, driven by organic growth, end of global destocking, and integration of acquired businesses.

• Normalised EBITDA nearly doubled to $7.9M, reflecting improved operational efficiency and cost reduction initiatives.

• Operating NPATA was $1.0M, slightly down from $1.3M year-over-year due to tax impacts; statutory NPAT was a loss of $3.5M.

• Order book expansion and integration synergies from acquisitions (LEAP Technologies, Axel Semrau) contributed to momentum and future growth.

• The company operates globally with over 600 employees and seven manufacturing sites, focusing on analytical and life sciences products for blue-chip customers.

Financial highlights

• Group net revenue reached $81.0M, a 6.0% increase year-over-year; gross profit increased 1.7% to $29.3M, with total gross margin at 36.2%.

• Normalised EBITDA rose to $7.9M, up 97.2% from $4.0M in the prior year; proforma gross margin held steady at 39.7%.

• Free cash flow increased to $6.6M from $2.6M year-over-year; cash flow from operations improved to $6.1M from $3.7M.

• Net debt reduced by $2.3M in H1 to $30.6M, with net leverage ratio below 2x; cash balance at period end was $10.4M.

• No interim dividend declared; cash flow predictability could support future dividends subject to board approval.

Outlook and guidance

• FY25 net revenue guidance maintained at $160.0M–$165.0M; nEBITDA guidance at $17.0M–$19.0M.

• Management expects continued improvement in operating cash flow, with margin expansion anticipated in H2 driven by product mix and pricing actions.

• Components & Consumables expected to maintain historical growth rates, supported by pharmaceutical sector recovery.

• Microsampling portfolio in Disruptive Technologies expected to reach nEBITDA breakeven for FY25.

• Malaysia manufacturing site expected to provide a lower cost base and capacity for forecast growth.